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Adenosine displays contradictory effects on cell
growth: it improves cell proliferation, but it may
also induce apoptosis and impair cell survival.
Following the pharmacologic characterization of
adenosine receptor expression on the human mela-
noma cell line A375, we chose A375 as our cellular
model to de®ne how the extracellular adenosine sig-
nals are conveyed from each receptor. By using
selective adenosine receptor agonists or antagonists,
we found that A2A stimulation reduced cell viability
and cell clone formation, whereas, at the same time,
it improved cell proliferation. In support of this ®nd-
ing we demonstrated that the stimulation of A2A
adenosine receptors stably expressed in Chinese ham-
ster ovary cell clone reproduced deleterious effects
observed in human melanoma cells. A3 stimulation
counteracted A2A-induced cell death but also
reduced cell proliferation. Furthermore, we found
that A3 stimulation ensures cell survival. We demon-
strated that adenosine triggers a survival signal via A3
receptor activation and it kills the cell through A2A
receptor inducing a signaling pathway that involves
protein kinase C and mitogen-activated protein
kinases. Key words: adenosine receptors/apoptosis/cell pro-
liferation/melanoma/molecular signaling. J Invest Dermatol
119:923±933, 2002
A
denosine displays contradictory effects: it has been
reported that adenosine improves and impairs cell
proliferation (Ethier and Dobson, 1997; MacLaughlin
et al, 1997; Fishman et al, 1998, 2000; Barry and Lind,
2000; Brown et al, 2000), induces apoptosis and cell
death (Kohno et al, 1996; Barry and Lind, 2000; Fishman et al,
2000; Shneyvays et al, 2000), but also displays heart and brain
cytoprotective functions during ischemia. Furthermore, adenosine
affects the immune system by exerting immunosuppressive and
anti-in¯ammatory activities (Ralevic and Burnstock, 1998).
Extracellular adenosine interacts with cells by two means: at
nanomolar and micromolar concentrations adenosine exerts its
effects as a consequence of the binding and activation of
speci®c cell surface receptors; at higher doses (millimolar
concentrations), it produces toxic effects probably by interfering
with the homeostasis of the intracellular nucleotide pool
(Schrier et al, 2001).
Four different adenosine receptors have been identi®ed and
pharmacologically characterized: A1, A2A, A2B, and A3 (Fredholm
et al, 2001). These receptors are seven transmembrane glycoproteins
coupled with G proteins and are widely distributed in human
tissues and organs. A2A and A2B receptors are coupled to adenylate
cyclase activity and their stimulation increases the intracellular
cyclic adenosine monophosphate concentration. A1 and A3
receptor stimulation decreases cyclic adenosine monophosphate
(cAMP) concentration and raises intracellular Ca2+ levels by a
pathway involving phospholipase C (PLC) activation (Abbracchio
et al, 1995; Fredholm et al, 2001).
The immunosuppressive and anti-in¯ammatory effects of
adenosine together with the increased extracellular concentration
found in tumor masses, have prompted us to hypothesize that
adenosine receptors could play a part in tumor development,
diffusion, and immunoescaping (Blay et al, 1997; Barry and Lind,
2000; Ohana et al, 2001).
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The molecular mechanisms supporting adenosine effects on
different normal and tumoral tissues have not yet been carefully
explored. In particular, adenosine, acting at speci®c A2A receptors,
promotes wound healing in both normal animals and in animals
with impaired wound healing (Montesinos et al, 1997).
Furthermore, adenosine stimulates angiogenesis in the dermis,
increases collagen and glycosaminoglycan production from ®bro-
blasts (Ethier et al, 1993; Ethier and Dobson, 1997). More recently,
it has been demonstrated that treatment of human keratinocytes
with adenosine may arrest keratinocyte proliferation (Brown et al,
2000). Moreover, A3 adenosine receptor blocks ultraviolet irradi-
ation-induced apoptosis in mast-like cells (Gao et al, 2001).
It is well known that ultraviolet radiation is associated with
cutaneous malignant melanoma (Landi et al, 2002). Excessive
exposure to ultraviolet among Caucasians is the main etiologic
factor implicated in the incidence of melanoma, a serious form of
skin cancer (MacKie, 1998). In view of these hallmarks, clari®ca-
tion of the cellular and biochemical mechanisms of adenosine may
be important for the understanding of its possible role in the
pathogenesis of tumors of the skin, such as basal cell carcinoma,
squamous cell carcinoma, and melanoma.
Because the contradictory effects of adenosine appear to be
triggered by the simultaneous engagement of different adenosine
receptor subtypes, a complete pharmacologic characterization of
the type and the number of the expressed adenosine receptors is
required for the understanding of adenosine's roles (Ohana et al,
2001). Recently, we have characterized the expression pattern of
the adenosine receptors on the surface of human melanoma A375
cells and documented the ability of these receptors to signal after
selective agonists binding (Merighi et al, 2001). A375 cells are an
established human melanoma cell line that belongs to a relatively
undifferentiated and highly metastatic class of melanocytic cells
with epithelioid shape and absence of pigmentation (Okazawa et al,
1998). In these cells mRNA for all four adenosine receptor
subtypes was detected. The A2A and A3 receptor proteins are
present at high levels on the cell surface (220 6 7 and
291 6 50 fmol per mg of protein, respectively), whereas A1
receptors are present in a lower amount (23 6 7 fmol per mg of
protein). The lack of commercially available selective radioligands
for A2B (Klotz et al, 1998) prevented direct labeling of this receptor
subtype in A375 cells and similar systems containing other
adenosine receptors; however, functional studies indicate that
A375 cells express an A2B-adenosine receptor coupled positively to
adenylyl cyclase (Merighi et al, 2001).
In this study we investigated the effects of adenosine on cell
proliferation, colony formation ability, and on the balance between
cell survival and cell death in A375 cells. Furthermore, Chinese
hamster ovary (CHO) cells stably transfected with human
recombinant adenosine receptors were used to con®rm the role
of adenosine receptors.
MATERIALS AND METHODS
Chemicals and reagents A375 cells were obtained from American
Tissue Culture Collection (ATCC). CHO cells transfected with the
human recombinant A1, A2A, and A3 adenosine receptors (CHO-hA1,
CHO-hA2A, CHO-hA3) were prepared as described earlier (Klotz et al,
1998). Tissue culture media and growth supplements were obtained
from BioWhittaker (Bergamo, Italy). 2-hexynyl-5¢N±ethylcarboxamido-
adenosine (HENECA), was a kind gift of Prof. G. Cristalli, University of
Camerino, Italy; N6(3-iodobenzyl)2-chloroadenosine-5¢N±methyluron-
amide (Cl-IB-MECA) and 1,3-dipropyl-8-cyclopentyl-xanthine
(DPCPX), were from RBI (Milano, Italy; 7-(2-phenylethyl)2-(2-
furyl)pyrazolo[4,3e]1,2,4-triazolo[1,5c]pyrimidine (SCH 58261), 5N-(4-
methoxyphenyl-carbamoyl)amino-8-propyl-2-(2-furyl)-pyrazolo-[4,3e]1,2,4-
triazolo[1,5-c]pyrimidine (MRE 3008F20), 5N-(4-phenylcarbamoyl)amino-
8-propyl-2-(2-furyl)pyrazolo[4,3e]1,2,4-triazolo[1,5c]pyrimidine (MRE
3055F20), and 5N-(4-phenyl-carbamoyl)amino-8-butyl-2-(2-furyl)-
pyrazolo-[4,3e]-1,2,4-triazolo[1,5-c]pyrimidine (MRE 3062F20) were
synthesized by Prof. P.G. Baraldi, University of Ferrara, Italy. Adenosine
was dissolved in Dulbecco's modi®ed Eagle's medium (DMEM) and
stored at ±80°C. HENECA, Cl-IB-MECA, SCH 58261, MRE
3008F20, MRE 3055F20, MRE 3062F20, and DPCPX were dissolved
in dimethylsulfoxide (DMSO) and stored at ±20°C. H89, N-[2-((p-
bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 2XHCE [a
selective inhibitor of protein kinase A (PKA)], chelerythrine-D [a
selective inhibitor of protein kinase C (PKC)], staurosporine (a potent
broad spectrum inhibitor of protein kinases A, C, and G), 2-amino-3-
methoxy¯avone [(PD 98059) a selective inhibitor of mitogen-activated
protein (MAP) kinase kinase (MEK)] and Z-Val-Ala-Asp(OMe)-CH2F
(Z-VAD-FMK) (a highly speci®c and irreversible inhibitor of caspases,
including caspase-1, -3, -4, and -7) were obtained from Calbiochem
(Milano, Italy). U0126 (an inhibitor of MEK-1 and MEK-2) and Anti-
ACTIVEâ MAPK polyclonal antibodies (pAb) and anti-ERK 1/2 pAb
were from Promega (Milano, Italy). RNAse was purchased from
Boehringer (Milano, Italy). [3H]Thymidine was obtained from NEN.
Mitochondrial dehydrogenase activity was measured by 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT). Unless
otherwise noted, all other chemicals were purchased from Sigma
(Milano, Italy).
Cell culture A375 cells were grown adherently and maintained in
DMEM, containing 10% fetal bovine serum, penicillin (100 U per ml),
streptomycin (100 mg per ml), and L-glutamine (2 mM) at 37°C in 5%
CO2/95% air.
The CHO-hA1, CHO-hA2A, and CHO-hA3 cellular clones were
grown adherently and maintained in DMEM with nutrient mixture F12,
containing 10% fetal bovine serum, penicillin (100 U per ml), strepto-
mycin (100 mg per ml), L-glutamine (2 mM), and geneticine (G418)
0.2 mg per ml at 37°C in 5% CO2/95% air.
Cells were passaged two or three times weekly at a ratio between
1 : 5 and 1 : 10.
Metabolic inhibitors Cells labeled for the JAM test (Matzinger, 1991)
were treated for 30 min with metabolic inhibitors or with drug vehicle
(DMSO) prior to being challenged with adenosine or adenosine analogs.
After 24 h, cells were harvested for DNA-lost quanti®cation. H89 was
used at 100 mM as a PKA inhibitor; Chelerytrine-D was used at 2 mM as
a PKC inhibitor; Staurosporine was used at 100 nM as a PKA, PKC, and
protein kinase G inhibitor. PD 98059 was used at 20 mM as an inhibitor
of MEK to prevent MEK-1 activation. U0126 was used at 10 mM as
inhibitor of MEK-1 and MEK-2 to prevent extracellular signal-regulated
kinase (ERK)-1 and ERK-2 activation. Z-VAD-FMK was used at 1 mM
as an irreversible inhibitor of caspase-1, -3, -4, and -7.
MTT assay The number of living cells was determined by evaluating
the mitochondrial dehydrogenase activity by using MTT that is
converted into a formazan product in living cells. Cells (105) were plated
in 24-multiwell plates; 500 ml of complete medium were added to each
well with different concentrations of adenosine receptor agonists and
antagonists. The cells were then incubated for 24 h. At the end of the
incubation period, 50 ml of MTT solution (5 mg per ml) were added to
each well. The plates were incubated for 2 h at 37°C then 550 ml of an
acid propanol solution (0.1 M HCl in isopropanol) were added to each
well to dissolve the formazan. The optical density of each well was read
on a spectrophotometer at 570 nm. For each experiment, four individual
wells of each drug concentration were prepared. Each experiment was
repeated three times.
JAM test This assay allows us to analyze cell death (apoptotic plus
necrotic cells) by performing the quanti®cation of the amount of
fragmented DNA. Target cells were labeled with 1 mCi per ml of
[3H]thymidine for 20 h in DMEM containing 10% fetal bovine serum,
penicillin (100 U per ml), streptomycin (100 mg per ml), and L-
glutamine (2 mM). The cells were then washed and treated with new
unlabeled medium containing adenosine or other analogs for 24 h. At
the end of the incubation period the cells were trypsinized and dispensed
in four wells of a 96 well plate, ®ltered through Whatman GF/C glass-
®ber ®lters using a Micro-Mate 196 cell harvester (Packard Instrument
Company, Pero, Italy). The ®lter bound radioactivity was counted on
Top Count Microplate Scintillation Counter (ef®ciency 57%) with
Micro-Scint 20.
The amount of apoptotic and necrotic cells, measured as the loss of
radioactivity associated with the loss of fragmented and degraded DNA,
was detected by ®ltration and subsequent washing with a Micro-Mate
196 cell harvester followed by quanti®cation with a Top Count
Microplate Scintillation Counter.
The percentage of cell death is expressed as 100 3 (dpm(U) ± dpm(T))/
dpm(U) were dpm(U) is the radioactivity of untreated cells and dpm(T) is
the radioactivity of treated cells (Secchiero et al, 2001).
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[3H]thymidine incorporation: cell proliferation test Cells were
seeded in fresh medium with 1 mCi of [3H]thymidine per ml in DMEM
containing 10% fetal bovine serum, penicillin (100 U per ml),
streptomycin (100 mg per ml), and L-glutamine (2 mM), and
simultaneously treated with adenosine or other analogs. After 24 h of
labeling, cells were trypsinized, dispensed in four wells of a 96-well plate,
and ®ltered through Whatman GF/C glass-®ber ®lters using a Micro-
Mate 196 cell harvester (Packard Instrument Company). The ®lter
bound radioactivity was counted on Top Count Microplate Scintillation
Counter (ef®ciency 57%) with Micro-Scint 20.
Colony formation assay Exponentially growing cells were seeded at
300 cells per well in six-well plates with 2 ml of fresh medium [DMEM
containing 10% fetal bovine serum, penicillin (100 U per ml),
streptomycin (100 mg per ml), and L-glutamine (2 mM) for A375 cell
line; DMEM-F12 containing 10% fetal bovine serum, penicillin (100 U
per ml), streptomycin (100 mg per ml), L-glutamine (2 mM), G418
0.2 mg per ml for stable transfected CHO cell lines] and treated with
adenosine or other analogs dissolved in DMSO solution. Control plates
received the same volume of DMSO alone. After 7 d of growth at 37°C
in humidi®ed atmosphere containing 5% CO2, the cells were ®xed with
absolute methanol for 5 minutes and stained with 1/10 Giemsa/
phosphate-buffered saline (PBS) staining solution for 10 min. Staining
solution was removed and colonies of greater than 30 cells were scored
as survivors. For each treatment, six individual wells were scored.
Flow cytometry analysis A375 adherent cells were trypsinized, mixed
with ¯oating cells, washed with PBS and permeabilized in 70% (v/v)
ethanol/PBS solution at 4°C for at least 24 h. The cells were washed
with PBS and the DNA was stained with a PBS solution, containing
20 mg per ml of propidium iodide and 100 mg per ml of RNAse, at
room temperature for 30 min point Cells were analyzed by FACScan
(Becton-Dickinson, Milano, Italy) and the content of DNA was
evaluated by the Cell-LISYS program (Becton -Dickinson). Cell
distribution among cell cycle phases and the percentage of apoptotic cells
were evaluated as previously described (Secchiero et al, 2001). Brie¯y,
the cell cycle distribution is shown as the percentage of cells containing
2n (G1 phase), 4n (G2 and M phases), and 4n > 3 > 2n DNA amount
(S phase) judged by propidium iodide staining. The apoptotic population
is the percentage of cells with DNA content lower than 2n.
Morphologic analysis To recover all seeded cells, the adherent
culture fraction was trypsinized and mixed with the supernatant fraction.
Then, the cell suspension was spun to a slide by cytospin 3 (Shandon,
Cheshire, U.K.) at 250 r.p.m. (500 g) for 10 min. As previously
described (Secchiero et al, 2001), cells were ®xed in 4%
paraformaldehyde for 10 min, permeabilized in PBS solution containing
0.1% of Triton X-100, and the DNA was stained with 4¢,6¢,-diamino-2-
phenyl-indole. Slides were mounted in (1±4-diazibicyclo[2,2,2]octane
(DABCO) glycerol-PBS and observed on Zeiss Axiophot ¯uorescent
microscope.
Immuno¯uorescence detection of activated ERK-1 and ERK-
2 ERK-1 and ERK-2 were detected by Anti-ACTIVEâMAPK pAb.
Anti-ACTIVEâMAPK pAb is an af®nity-puri®ed rabbit serum that
speci®cally recognizes the dually phosphorylated active forms of MAP
(also known as p44/ERK-1 and p42/ERK-2) enzymes.
A375 cells were seeded on glass coverslips in 24-well plates by
overnight growth at 37°C in humidi®ed atmosphere containing 5%
CO2. A375 cells were treated with 100 mM of adenosine or with 10 mM
of Cl-IB-MECA, MRE 3008F20, and SCH 58261, or with 100 nM of
HENECA. After 15 or 30 min the medium was removed, cells were
washed two times with PBS, ®xed in 10% paraformaldehyde for 30 min,
permeabilized in a PBS solution containing 0.1% of Triton X-100 and
incubated for 30 min with PBS plus 5% goat serum and 0.5% bovine
serum albumin. The cells were then stored for 24 h at 4°C in a
humidi®ed chamber with 30 ml of a 1 : 200 dilution of Anti-
ACTIVEâMAPK pAb solution containing 0.5% of goat serum and 0.5%
of bovine serum albumin in PBS. Excessive antibody was washed away
with PBS and rabbit antibodies were detected with ¯uorescein isothio-
cyanate-labeled goat anti-rabbit IgG. Coverslips were stained with 4¢,6¢,-
diamino-2-phenyl-indole, mounted in DABCO glycerol-PBS and
observed on Zeiss Axiophot ¯uorescent microscope.
Western blotting The phosphorylation and activation of ERK-1 and
ERK-2 was detected by western blotting using the Anti-
ACTIVEâMAPK pAb, according to the manufacturer's protocol.
Brie¯y, A375 cells were starved for 5 d and treated with 100 mM of
adenosine or with 10 mM of Cl-IB-MECA, MRE 3008F20, SCH 58261,
or with 100 nM of HENECA for 2 h. Cells were harvested and washed
with ice-cold PBS containing 1 mM sodium orthovanadate. Cells were
then lyzed in Triton lysis buffer. Equivalent amounts of protein (40 mg)
were subjected to electrophoresis on 10% sodium dodecyl sulfate±
acrylamide gel. The gel was then electroblotted on to a nitrocellulose
membrane. The membranes were probed with Anti-ACTIVEâMAPK
pAb (1 : 5000) in TBST (20 mM Tris±HCl pH 7.5, 150 mM NaCl,
0.05% Tween 20)/0.5% bovine serum albumin for 1 h at room
temperature. Filters were washed and incubated for 1 h at room
temperature with peroxidase-conjugated anti-rabbit immunoglobulin G
(1 : 5000). Speci®c reactions were revealed with the Enhanced
Chemiluminescence western blotting detection reagent (Amersham
Corp., Arlington Heights, IL). The membranes were then stripped and
reprobed with Anti-ERK 1/2 pAb, rabbit serum that cross-react with
total ERK to ensure equal protein loading.
Figure 1. A375 cell death induction by adenosine. The dose±
response curve of A375 cells sensitivity to adenosine is reported. A375
cells were treated with adenosine at indicated doses for 24 h and cell
death was quanti®ed by JAM test. Percentage of cell death
([3H]thymidine-labeled DNA loss) is reported in ordinate with SD error
(vertical bar). Values represent mean (6 SEM) of four separate DNA-lost
quanti®cation in the same experiment. 100% indicates 100% loss of
radioactivity incorporated by untreated cells. *p < 0.05 with respect to
control ``untreated cells''; analysis was by ANOVA followed by Dunnett's
test.
Figure 2. Role of A2A and A3 in adenosine-induced cell death on
A375 cells. A375 cells were treated with 1 mM of adenosine to induce
cell death quanti®ed by JAM test. Cells were pretreated with drug
vehicle (DMSO), with MRE 3008F20 1 mM, with SCH 58261 1 mM or
with MRE 3008F20 1 mM plus SCH 58261 1 mM. Vertical axis reports
percentage of cell death variation with respect to adenosine-induced cell
death: positive/negative values represent increase/decrease of adenosine-
induced cell death. Horizontal axis: ``D'' DMSO control, ``M'' MRE
3008F20, ``S'' SCH 58261, ``M + S'' MRE 3008F20 + SCH 58261.
Negative 100% (± 100%) indicates restored vitality. *p < 0.05 with
respect to control ``DMSO''; analysis was by ANOVA followed by
Dunnett's test.
VOL. 119, NO. 4 OCTOBER 2002 ADENOSINE RECEPTORS IN HUMAN MELANOMA CELLS 925
Statistical analysis All values in the ®gures and text are expressed as
mean 6 SD of n observations (with n > 3). Data sets were examined by
analysis of variance (ANOVA) and Dunnett's test (when required).
P < 0.05 was considered statistically signi®cant. Representative images
obtained by ¯uorescent microscope or by FACScan are reported, with
similar results having been obtained in at least three different
experiments.
RESULTS
Adenosine kills A375 via the A2A receptor A375 cells were
treated for 24 h with A2A or A3 selective agonists (HENECA and
Cl-IB-MECA) or antagonists (SCH 58261 and MRE 3008F20),
respectively (Baraldi et al, 2000; Klotz, 2000; Varani et al, 2000). By
using trypan blue exclusion, cell counts and metabolically induced
formazan production, we observed that MRE 3008F20, Cl-IB-
MECA, and HENECA produced small but reproducible toxic and
anti-proliferative effects (less than 10%) (data not shown). To
evaluate if the reduced number of viable cells quanti®ed by MTT
was due to a massive cell death or to a proliferative block, we
analyzed the effect of adenosine receptor stimulation on cell
survival by the JAM test. A375 cells, previously labeled with
[3H]thymidine, were treated for 24 h with increasing amounts of
adenosine. Adenosine induced cellular death (apoptosis and
necrosis) in a concentration-dependent manner, starting at
0.1 mM and reaching the maximal effect at 1 mM. Figure 1
shows a typical result with about 20% of A375 cells killed by
adenosine (1±3000 mM).
To establish if the A2A or A3 receptor translated the adenosine
cell death signal, we attempted to block single receptors by the
pretreatment of A375 cells with SCH 58261 (1 mM), MRE
3008F20 (1 mM), or DMSO (as negative control) for 30 min
before addition of adenosine at 1 mM. Figure 2 shows that SCH
58261 was able to inhibit up to 95 6 10% of adenosine-induced
deleterious effects (bar labeled with ``S'') thereby promoting cell
survival with respect to control cells (bar labeled with ``D''). In
contrast, MRE 3008F20 exerted the opposite effect, increasing
adenosine-mediated cell death up to 75 6 11% (bar labeled with
``M''). This prompted us to hypothesize that adenosine stimulation
via A2A receptors induces cell death (apoptosis and/or necrosis),
whereas A3 signaling has a protective effect on cell survival in the
presence of 1 mM extracellular adenosine. When MRE 3008F20
and SCH 58261 were tested simultaneously on adenosine-treated
cells (Fig 2; bar labeled with ``M + S''), we found a small increase
of adenosine-induced cell death (25 6 7%), suggesting that A3
protective signaling also counteracted A2A-independent deleterious
signals (autogenous cell death, cell aging). Similar results were
obtained with 0.3 mM and 10 mM of adenosine (data not shown).
To illustrate the role of the A1 and A2B receptors on adenosine-
induced cell death, A375 cells were preincubated for 30 min with
1, 10, 100, and 500 nM of the antagonist DPCPX (Klotz et al,
1998) and then exposed to 1, 10, and 100 mM of adenosine for
24 h. DPCPX did not prevent cell death, supporting the notion
that A1 and A2B receptors do not play a part in adenosine-induced
necrotic and/or apoptotic cell death signaling (data not shown).
A375 cells were treated for 24 h with increasing amounts of
adenosine analogs to characterize the capability of A2A and A3
receptor activation to induce or prevent A375 cell death,
respectively. HENECA induced cell death in a concentration-
dependent manner reaching a maximum of activity at about
100 nM, although it was less active at higher doses (Fig 3,
diamonds). SCH 58261 (Fig 3, ®lled triangles) did not exert any
effect as did Cl-IB-MECA (Fig 3, open squares). MRE 3008F20
promoted a concentration-dependent cell death response reaching
30 6 4% at 10 mM (Fig 3, ®lled circles). MRE 3008F20 was tested
only up to 10 mM due to limited solubility. We also tested two
different antagonists with a high af®nity for A3 adenosine receptors
(Merighi et al, 2001): MRE 3055F20 and MRE 3062F20.
Figure 3. Cell death induction by HENECA, Cl-IB-MECA, MRE
3008F20, and SCH 58261 of A375 cell line evaluated 24 h after
drug treatment by JAM test. Cell death is expressed in ordinate as
percentage of DNA lost vs untreated cells. Cells treated with 0.3±
3000 nM of HENECA (r), with 0.3±30 mM of Cl-IB-MECA (h), 0.3±
10 mM of MRE 3008F20 (d) and 0.3±30 mM of SCH 58261 (m) are
reported. 100% indicates 100% loss of radioactivity incorporated by
untreated cells. *p < 0.05 with respect to untreated cells; analysis was by
ANOVA followed by Dunnett's test.
Table I. Quanti®cation of A375 DNA content by propidium-iodide staining and ¯ow analysis
Treatment Dose
Cell cycle analysisb Apoptosis detection
G1 S G2/M Subdiploid cells
a
DMSO 44 6 2 13 6 2 43 6 1 4 6 1
Cl-IB-MECA 10 mM 58 6 2d 11 6 2 31 6 2d 3 6 1
HENECA 0.001±10 mMc 44 6 2 13 6 1 43 6 2 3 6 1
MRE 3008F20 10 mM 42 6 1 11 6 1 47 6 1 8 6 1d
SCH 58261 10 mM 40 6 2 14 6 2 46 6 2 4 6 1
Untreated 44 6 2 13 6 2 43 6 2 4 6 1
Adenosine 1±300 mMc 43 6 3 14 6 1 43 6 2 5 6 1
Adenosine 1 mM 30 6 1e 46 6 2e 24 6 1e 11 6 2e
Adenosine 3 mM 32 6 2e 36 6 1e 32 6 2e 20 6 2e
aValues are % of total culture showing sub-diploid DNA content (< 2n).
bValues are % of living cells with normal DNA content (>2n).
cHENECA was used at 1, 3, 10, 30, 100, 300, 1000, 3000, and 10000 nM and adenosine at 1, 3, 10, 30, 100, and 300
mM and the results obtained with these concentrations were reported as mean 6 SD of at least three different experiments.
dp < 0.05 vs DMSO.
ep < 0.05 vs untreated.Statistical analysis was by ANOVA followed by Dunnett's test.
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Likewise, these drugs, tested in the range 0.3±10 mM for 24 h,
induced A375 necrotic and/or apoptotic cell death in a concen-
tration-dependent manner reaching maximum activity between 1
and 10 mM (20 6 2%) (data not shown).
To de®ne if the cell death signal triggered by A2A receptor
stimulation or by A3 silencing was an apoptosis program, we
investigated cellular morphology of A375 drug-treated cells.
Typical apoptotic features, characterized by nuclear condensation
and fragmentation, were detected after 3 mM adenosine treatment
but not with lower doses (data not shown). Apoptotic cells were
occasionally detected also with 10 mM MRE 3008F20. Notably,
necrotic cells, characterized by extensive membrane damage
(irregular swelling). Cells treated with 10 mM SCH 58261,
100 nM HENECA, and 10 mM Cl-IB-MECA were similar to
control test (DMSO-treated cells, data not shown).
To quantify the number of apoptotic cells we analyzed the
cellular DNA content by ¯ow cytometry after propidium-iodide
nuclear staining. Any signi®cant difference in the amount of
apoptotic DNA detected in cultures treated with HENECA (from
1 to 10,000 nM), 10 mM Cl-IB-MECA or 10 mM SCH 58261 with
respect to DMSO-treated cells is listed in Table I. Only MRE
3008F20 was able to induce apoptosis slightly (8% vs 4%).
Adenosine did not induce apoptosis when added at concentrations
less than 1 mM, whereas massive apoptosis was noted at 1 and 3 mM
(up to 20%). These data agree with those obtained observing cell
morphology: A375 cells preferentially die from a nonapoptotic
program when treated with MRE 3008F20, HENECA, and
adenosine (from 1 to 300 mM).
Analysis of A375 distribution among the different phases of the
cell cycle was also performed. Only Cl-IB-MECA was able to alter
the amount of cells in the different phases of the cell cycle. The
accumulation of cells in the G1 phase was increased by 32% with a
corresponding decrease of cells in G2/M (by 28%; p < 0.05).
HENECA (1±10 000 nM), MRE 3008F20, and SCH 58261 (at
10 mM) did not exert any effect compared with DMSO-treated
cells. With adenosine in concentrations up to 300 mM no effect on
the cell cycle was noted. Interestingly, millimolar doses of
adenosine, that induced apoptosis, produced a decrease in the
amount of cells in G1 and a strong accumulation in S phase with
respect to untreated cells.
Adenosine receptors in A375 proliferation To evaluate better
if adenosine could interfere with cell proliferation, A375 cells were
treated with increasing amounts of adenosine and the proliferation
rate was determined by [3H]thymidine incorporation assay (Fig 4,
open circle), which is more sensitive than ¯ow cytometry for the
evaluation of cell proliferation. Only small increases in cell growth
were observed with the addition of 100 or 300 mM extracellular
adenosine (10 6 2%). In agreement with ¯ow cytometry analysis,
adenosine at millimolar concentrations impaired cell proliferation
up to 60 6 5%. To establish which receptor induces the adenosine
modulation of cell proliferation, A375 cells were treated with
increasing concentrations of adenosine plus A2A (1 mM SCH 58261)
or A3 (1 mM MRE 3008F20) selective antagonists followed by cell
Figure 4. Effect of MRE 3008F20 (1 mM) and SCH 58261 (1 mM)
on adenosine-mediated proliferation. A375 proliferation was
monitored by [3H]thymidine incorporation for 24 h. Proliferation
rate at different adenosine concentrations (from 3 to 3000 mM) is
reported in ordinate as percentage of [3H]thymidine incorporation of
mock untreated cells. Reported values represent the mean of four
[3H]thymidine incorporation quanti®cations with SD (vertical bar). The
graph reports A375 adenosine-induced proliferation curves under
treatment with MRE 3008F20 (m), with SCH 58261 (j) or DMSO
(s). 100% indicates the thymidine incorporation of untreated cells. *p
< 0.05 with respect to untreated cells; analysis was by ANOVA followed
by Dunnett's test.
Figure 5. A2A and A3 role on A375 cell-proliferation by
[3H]thymidine incorporation test. A375 cells were treated with
HENECA (e), with Cl-IB-MECA (s), with MRE 3008F20 (d), and
with SCH 58261 (m) at the indicated concentrations. [3H]thymidine
incorporation is reported as percentage of DNA-labeled recovered on
drug vehicle-treated cells. Ordinate reports means of four different
[3H]thymidine incorporation quanti®cations with SD (vertical bar). 100%
indicates the thymidine incorporation of untreated cells. *p < 0.05 with
respect to untreated cells; analysis was by ANOVA followed by Dunnett's
test.
Figure 6. Kinetic analysis of A375 starved cells progression
through S cell cycle phase and evaluation of Cl-IB-MECA
interference. Starved A375 cells were challenged with new medium
containing no serum and vehicle DMSO (s); with 10% of serum and
Cl-IB-MECA vehicle DMSO (d); with 10% of serum and 10 mM of
Cl-IB-MECA (m). At the indicated time A375 cells were pulsed with
[3H]thymidine for 2 h and mean of four separate [3H]thymidine
incorporations was reported with SD (vertical bar) as ordinate.
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proliferation analysis by [3H]thymidine incorporation assay. MRE
3008F20 (Fig 4, ®lled triangle) enhanced adenosine-induced
proliferation in contrast to SCH 58261, which annihilated
adenosine's proliferative effect (Fig 4, ®lled square). Remarkably,
adenosine at millimolar concentrations arrested cell proliferation
even in the presence of MRE 3008F20 and SCH 58261. When
using the A1 and A2B antagonist DPCPX at 10, 100, and 500 nM,
no alteration in adenosine-induced proliferation was observed,
leading us to exclude that the A1 and A2B receptors could be the
mediators of adenosine-induced proliferation (data not shown). To
verify if adenosine promotes cell proliferation via A2A and impairs
cell proliferation via A3, we performed a dose±response growth
curve by treating A375 cells with increasing concentrations of A2A
(HENECA, SCH 58261), and A3 (Cl-IB-MECA, MRE 3008F20)
agonists and antagonists, respectively. As shown in Fig 5,
HENECA (diamonds) induced a small but signi®cant increase in
cell proliferation (up to 8%), whereas a decrease in cell growth was
observed after SCH 58261 treatment (Fig 5, ®lled triangles). These
data support the role of A2A as a positive modulator of A375 cell
proliferation, also under tonic stimulation by basal adenosine levels.
Speci®c stimulation of the A3 receptor by Cl-IB-MECA caused
a reduction of A375 proliferation with a 75 6 6% of inhibition at
30 mM (Fig 5, open circles). We observed that MRE 3008F20 had
negligible effects on A375 cell growth (Fig 5, ®lled circles) because
we hypothesize that the loss of [3H]thymidine incorporation
observed in Fig 5 is probably due, to a major extent, to the
induction of cell death and not a block of proliferation (see Fig 3,
®lled circles).
We have performed further studies to consider the role of A3 on
cell proliferation. To evaluate if A3 stimulation delays the
progression to S cell cycle phase or blocks a subset of A375
population in G1, A375 cells were synchronized in G0±G1 phase by
starvation in serum-free medium for 72 h. Starved cells were then
resuspended in fresh medium with 10% serum and labeled with
[3H]thymidine for 2 h at different time points. Figure 6 shows that
A375 cells entered into S phase 13 h after serum administration
(®lled circle), whereas starved cells cultured in medium without
serum (open circle) incorporated an insigni®cant amount of
[3H]thymidine. When 10 mM of Cl-IB-MECA was added to
A375 cells after starvation (Fig 6, ®lled triangle), the cells
continued to enter into S phase at 13 h postserum addition, but
the maximum amount of [3H]thymidine incorporation was only
64% of the control. During the same experiment, cells were
analyzed by FACScan to quantify cell distribution among the cell
cycle phases. Figure 7(A) shows that starved cells were blocked in
G1 (75%), whereas 18 h postserum addition (Fig 7B) A375 cells
were forced into S (20%) and G2/M (35%) phases. Cl-IB-MECA
(Fig 7C) signi®cantly impaired the serum-induced cell transition
from G0/G1 to S phase (16 6 1% instead of 20 6 1%, p < 0.05)
and to G2/M phase (30 6 1% instead of 35 6 1%, p < 0.05),
thereby supporting the hypothesis that A3 stimulation blocks the
transition into G1 without affecting DNA synthesis. Finally, we
emphasize that Cl-IB-MECA reduces [3H]thymidine incorpor-
ation in the presence of 1 mM DPCPX and SCH 58261 (as A1 and
A2A antagonist, respectively) proving that Cl-IB-MECA acts
through A3 receptor interaction (data not shown).
The A3 receptor: protective effects We also investigated the
role of the simultaneous stimulation of A2A and A3 adenosine
receptors on cell survival. In a new set of experiments HENECA-
treated cells (30, 100, and 300 nM) were incubated with increasing
amounts of Cl-IB-MECA (1, 3, and 10 mM) and the residual
necrotic and/or apoptotic cell death was quanti®ed by the JAM
test. We observed that A3 stimulation reduced HENECA-induced
cell death and promoted cell survival in a concentration-dependent
fashion. Figure 8(A) summarizes the data obtained with 100 nM
HENECA; Cl-IB-MECA abolished not only HENECA-induced
cell death, but also increased cell survival up to 26 6 2% with
respect to control cells (DMSO treated). Similar results were
obtained with 30 and 300 nM HENECA (data not shown),
suggesting distinct roles for the A2A and A3 receptors.
To verify if tonic stimulation (mediated by basal extracellular
adenosine) of A2A receptors would have a deleterious effect on cell
survival impaired during A3 blockage, A375 cells were treated with
A2A or A3 antagonists (1 mM SCH 58261 and 1 mM MRE 3008F20,
respectively), alone or in combination. Figure 8(B) illustrates that
cell death promoted by MRE 3008F20 (bar labeled with ``M'') was
abolished by SCH 58261 (bar labeled with ``M + S''), supporting
the hypothesis that the A2A receptor triggers cell death also under
tonic stimulation.
To evaluate further the effects of adenosine on the clonogenic
ability of A375 cells, we performed colony formation assays. Cl-IB-
MECA promoted cell survival, increasing the number of colonies
to as much as 185 6 20% (Fig 9A), whereas HENECA impaired
the clonogenic potential of A375 cells (Fig 9B). As expected, A2A
receptor blockage by SCH 58261 increased colony number
(Fig 9D). A3 silencing produced a strong negative effect, deleting
Figure 7. DNA content analysis of A375 starved cells by ¯ow cytometry. Density curves show relative cell number (vertical axis) vs propidium-
iodide ¯uorescence (PI = right horizontal axis) and cell size (left horizontal axis). Cells in different cycle phases (G1, S, and G2/M) and relative
percentages of distribution are reported in each panel. (A) Starved A375 cells treated for 18 h with new medium containing no serum. (B) Starved
A375 cells treated for 18 h with new medium containing 10% of serum. (C) Starved A375 cells treated for 18 h with new medium containing 10% of
serum and 10 mM of Cl-IB-MECA. (A,B) A375 cells were challenged with Cl-IB-MECA vehicle (DMSO). A representative of four separate
experiments is shown.
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by 48 6 2% the number of colonies when MRE 3008F20 was
applied at 10 mM (Fig 9C).
This assay provides additional evidence that A2A is deleterious,
whereas A3 is necessary and useful for A375 cell culture growth.
The human A2A receptor induces cell death in CHO cell
line To verify whether the A2A receptor is able to induce
necrotic and/or apoptotic cell death when expressed in a
nonhuman cell line, CHO-hA2A cells were treated with
HENECA (A2A±A3 agonist) or Cl-IB-MECA (A3 selective
agonist) and the amount of cell death was detected by the JAM
test. Figure 10 shows that HENECA (®lled triangles), but not Cl-
IB-MECA (open circles), caused the death of CHO-hA2A cells,
according to their different af®nity for the A2A receptor. To
ascertain that the HENECA killer effect was the consequence of
A2A receptor stimulation and not of CHO sensitivity to this
compound, CHO-hA1 and CHO-hA3 clones were treated with
HENECA and no cell death was observed by the JAM test (data
not shown). Of note, CHO-hA3 cells were not killed by MRE
3008F20 treatment, suggesting that the deleterious effects of MRE
3008F20 on A375 cells were a consequence of the abolishment of
the antagonistic effect of A3 on the A2A death signal pathway, and
not to a generic toxic effect.
To establish whether the A2A receptors expressed in CHO-hA2A
cells were able to maintain their ability to impair colony formation,
CHO-hA1, CHO-hA2A, and CHO-hA3 cells were treated with
increasing amounts of HENECA (ranging from 3 to 10,000 nM)
and residual clonogenic ability was monitored. HENECA impaired
clonogenicity of CHO-A2A clones, reducing the number of
residual colonies up to 60 6 5% when compared with untreated
cells. In contrast, HENECA was not effective on CHO-hA1 and
CHO-hA3 clones (mean of 110 6 3% and 92 6 6% of DMSO
control cells, respectively), further supporting the idea that A1 and
A3 human receptors were not able to kill CHO cells.
The A2A-induced death signaling pathway To investigate the
molecular mediators of the death signaling initiated by the surface
A2A adenosine receptor, A375 cells were treated with adenosine
(10 mM) in the presence of a panel of metabolic inhibitors, and cell
death was monitored by the JAM test, quantifying necrosis and/or
apoptosis.
Treatment with PD98059 or with U0126 (MEK-1 and MEK-2
inhibitors) abolished the adenosine effect (cell death was
3.3 6 2.2% and 4.5 6 2.3% vs 18.3 6 2.5%, respectively). PKC
inhibitors chelerythrine-D and staurosporine deleted the negative
effects of adenosine (cell death was ±0.6 6 1.7% and ±0.9 6 2.5%
vs 18.3 6 2.5%, respectively), whereas H89 (PKA inhibitor) and
Z-VAD-FMK (caspases inhibitor) did not prevent cell death
(Table II).
A375 cells were treated with 100 nM HENECA to induce cell
death (22.0 6 4.7%) speci®cally via A2A: as observed with
adenosine, the inhibitors of ERK kinases and of PKC prevented
cell death (±30.0 6 2.6%, ±32.1 6 3.2% and ±11.8 6 4.7%,
0.9 6 1.9%, respectively), whereas PKA and caspases inhibitors
did not affect HENECA killer effect (Table II). As expected, also
MRE 3008F20-induced cell death (31.0 6 4.3%) was sensitive to
MEK and PKC inhibitors (±16.8 6 1.0, 14.5 6 4.2, and
1.3 6 3.1, 12.7 6 0.9, respectively) because, during A3 blockage,
A2A tonic stimulation induces cell death (Table II).
ERK-1 and ERK-2 activation under adenosine, A2A
stimulation and A3 block The treatment of A375 cells with
HENECA 100 nM (Fig 11A, lane 2), MRE 3008F20 10 mM
(Fig 11A, lane 5), and adenosine 100 mM (Fig 11A, lane 6)
stimulated ERK-1 and ERK-2 activation. On the other hand, SCH
58261 10 mM and Cl-IB-MECA 10 mM (Fig 11A, lanes 3 and 4,
respectively) had no effect on the expression level of ERK-1 and
ERK-2 phosphorylated isoforms.
By using speci®c antibody targeting phosphorylated ERK-1
and ERK-2, we have also investigated the intracellular distri-
bution of activated ERK-1 and ERK-2 MAP kinases during
adenosine (10 mM), HENECA (100 nM), or MRE 3008F20
(10 mM) induced cell death. Figure 11B shows that faint
¯uorescence of anti-ERK-1 and anti-ERK-2 activated isoforms
was detected in cytoplasm of drug-vehicle cells (panel 3) but a
strong ¯uorescence was present in the nuclei of HENECA and
MRE 3008F20 treated cells (panels 1 and 4, respectively).
Activated ERK were detected also in nuclei of A375 cells after
30 min of treatment with adenosine (data not shown) but not
after Cl-IB-MECA (panel 2) and SCH 58261 challenge (data
not shown).
Lastly, we report that A375 cell proliferation is strongly
dependent on ERK activation: U0126 blocked [3H]thymidine
incorporation up to 63% and reduced the percentage of cells into S
phase up to 80% (data not shown).
Figure 8. Study of the effect on cell survival of simultaneous
stimulation of A2A and A3 receptors. After 24 h of treatment, cell
death was quanti®ed by JAM test. Percentage of cell death calculated as
mean of four different DNA-loss quanti®cations is reported in ordinate
with SD (vertical bar). Negative values indicate increase in cell survival
respect to A375 cells treated with drug vehicle (DMSO). 100% indicates
100% loss of DNA. (A) Variation of A2A-induced cell death by A3
stimulation. A375 cells treated with HENECA (100 nM) were challenged
with Cl-IB-MECA at the indicated concentrations reported in abscissa
(1, 3, and 10 mM). *p < 0.05 with respect to control ``0''; analysis was by
ANOVA followed by Dunnett's test. (B) Induction of cell death by 1 mM
of MRE 3008F20 (bar labeled with M), by 1 mM of SCH 58261 (bar
labeled with S) or by a combination of MRE 3008F20 and SCH 58261
(bar labeled with M + S). *p < 0.05 with respect to control ``DMSO'';
analysis was by ANOVA followed by Dunnett's test.
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DISCUSSION
In agreement with published reports showing that adenosine could
promote the growth of the tumor masses and cell proliferation
(Ethier and Dobson, 1997; MacLaughlin et al, 1997) and also impair
cell viability (Ongini and Schubert, 1998; Fishman et al, 2000;
Shneyvays et al, 2000), we have found that adenosine affected cell
proliferation (Fig 4) and also induced cell death (both apoptosis and
necrosis) of A375 human melanoma cell line (Fig 1). At the same
time numerous reports document that adenosine is able to impair
cell proliferation as well as to improve cell survival (Brown et al,
2000; Ohana et al, 2001). The underlying basis of these apparently
contradictory effects, however, is not yet clearly understood.
Role of adenosine receptors in A375 culture
growth Although the presence of all four adenosine receptor
subtypes has been documented in A375 melanoma cells (Merighi et
al, 2001), only A2A and A3 receptors seem to be involved in the
regulation of cell proliferation and survival. This is very surprising
as the A2B and A1 subtypes are signaling through the same
pathways, respectively. One explanation may be that their low
abundance in these cells is not suf®cient for productive effector
coupling.
In spite of a large body of literature, the role of A2A and A3 in
apoptosis and cell death induction remains incompletely under-
stood. Evidences from in vivo studies suggest that A2A block
achieved neuroprotection and support the view that A2A stimula-
tion is detrimental in neurons and also in thymocytes (Ongini and
Schubert, 1998; Apasov et al, 2000). Conversely, A2A receptor
activation appeared to reduce ischemia-reperfusion injury in the
kidney (Okusa et al, 2000). Different authors showed that at the
same time low concentrations of A3 receptor agonists have
protective effects and, in contrast, high concentrations of agonists
for A3 receptor can induce apoptosis. Recent studies suggested the
involvement of the A3 receptor in adenosine-induced apoptosis
using Cl-IB-MECA (in rat astrocytes, in human peripheral blood
mononuclear cells, in both myeloid and lymphoid cells, in cardiac
Figure 9. Modulation of A375 colony formation ability by adenosine receptors engagement. A375 cells were treated with Cl-IB-MECA (A),
HENECA (B), MRE 3008F20 (C), and SCH 58261 (D) at the indicated concentrations. Number of scored colonies is reported in ordinate as
percentage of DMSO-treated cells. Cell survival percentages reported are expressed as mean of six independent plating experiments with relative SD
(vertical bar). 100% indicates the 100% of the number of the colonies obtained with untreated cultures. *p < 0.05 with respect to control ``0''; analysis
was by ANOVA followed by Dunnett's test.
Figure 10. Cell death induction of CHO-hA2A clone by
HENECA and Cl-IB-MECA. CHO-hA2A cells were treated with
indicated concentrations of HENECA (m) or with Cl-IB-MECA (s)
for 24 h and cell death induction was quanti®ed by JAM test. Percentage
of cell death calculated as mean of four different DNA-loss
quanti®cations is reported in ordinate with SD (vertical bar). Drug
concentrations are reported in abscissa. 100% indicates 100% lost of
thymidine incorporation of untreated cells. *p < 0.05 with respect to
DMSO-treated cells; analysis was by ANOVA followed by Dunnett's test.
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myocytes) (Kohno et al, 1996; Yao et al, 1997; Abbracchio et al,
1998; Barbieri et al, 1998; Baraldi et al, 2000; Shneyvays et al, 2000);
however, further investigations on CHO-hA3 and on mast and
lymphoma cell lines (Brambilla et al, 2000; Fishman et al, 2000; Gao
et al, 2001) revealed no involvement of A3 receptors on cell death
induction, suggesting a role for A3 receptor signaling, which is
highly dependent on the cell- or tissue-speci®c context. We believe
that important new inroads in the research on A2A and A3 receptor
functions will come from understanding cells as complex systems in
which different receptors are coexpressed to serve as active
modulators in signal transduction. The interactions between them
will prove to be a critical mechanism determining cellular survival.
The rationale for such a concept comes from our experiments
showing that adenosine acts on A375 culture growth through two
independent mechanisms. One pathway seems to involve the
activation of A2A receptors playing a key role in cell death (Figs 2
and 3). A second pathway involves the A3 receptor that protects
A375 cell line from A2A-induced cell death (Fig 8A,B).
Analogously, A2A stimulation impaired plating ef®ciency of A375
cells (Fig 9B), whereas A3 exerted positive effects (Fig 9A).
Irrespective of the cytostatic effect promoted by A3 stimulation, the
A3 agonist improves clonal expansion. In this regard, we underline
that the colonies obtained under A3 stimulation are smaller and
formed by less cells than the untreated one. These observations
seem to support the simultaneous presence of the following
opposite effects after A3 receptor stimulation: an high clonogenic
ability and a low rate of proliferation. The ability of adenosine
receptors in modulating clonal potential of A375 cells (evaluated by
colony formation assay) may be the consequence of the interaction
with at least four biologic properties: (i) resistance to detachment
stress that induces apoptosis of adherent cells when cell adhesion is
impeded (anoikis); (ii) interference with cell adhesion mechanism;
(iii) inhibition of spontaneous cell cycle progression (G1±G0
transition) or recruitment of cell from G0; and (iv) survival of
cells committed to clonal expansion. Further support for the
opposite role of A2A and A3 receptors stems from experiments with
CHO cells expressing human A1, A2A, and A3 receptors. Human
recombinant adenosine receptors stimulation by agonists showed
that only the A2A subtype has the intrinsic ability to induce cell
death and to impair clonogenic potential of CHO cells. This ability
was not found for A1 and A3 receptors.
We underline that adenosine-induced apoptosis observed with
doses > 1 mM is receptor independent, as previously reported
(Schrier et al, 2001). In addition, we have observed a biphasic
behavior of HENECA (Fig 3), probably due to the lack of
selectivity. Consequently, we hypothesize that at low HENECA
concentrations (from 0.3 to 100 nM) A2A is the principal subtype
activated and exerts its deleterious role, but at higher HENECA
doses (> 300 nM) A3 stimulation becomes suf®ciently strong to
antagonize A2A killer effect, as obtained with Cl-IB-MECA
(Fig 8A).
We point out that these opposite roles of A2A and A3, discovered
under overstimulation, are also present during tonic adenosine
stimulation exerted by basal levels of this autacoid nucleoside. We
prove that the tonic stimulation of A3 receptors counter-balanced
the tonic killer effects mediated by A2A receptors (Fig 8B).
Molecular signaling of A2A activation Whereas A2A
activation plays a key part in cell death, adenosine also improves
A375 cell proliferation by A2A activation (Fig 4); on the other
hand, if A3 receptors protect the cells from A2A-induced cell death,
their stimulation blocks A375 proliferation (Fig 5), according to
the anti-apoptotic and anti-proliferative role of A3 previously
reported (Brambilla et al, 2000; Gao et al, 2001). Interestingly, we
observed that adenosine-induced cell proliferation followed by A2A
stimulation seems to involve MEK-1 and MEK-2 by increasing the
concentration of phosphorylated ERK-1 and ERK-2 isoforms with
marked nuclear localization (Fig 11B, panel 1). Our observations
Table II. Neutralization of adenosine, HE-NECA, and
MRE 3008F20 cell death signaling by metabolic inhibitors
Adenosine HE-NECA MRE 3008F20
DMSO 18.3 6 2.5 22.0 6 4.7 31.0 6 4.3
PD98059 3.3 6 2.2a ±30.0 6 2.6a ±16.8 6 1.0a
U0126 4.5 6 2.3a ±32.1 6 3.2a 14.5 6 4.2a
Chelerythrine-D ±0.6 6 1.7a ±11.8 6 4.7a 1.3 6 3.1a
Staurosporine ±0.9 6 2.5a 0.9 6 1.9a 12.7 6 0.9a
H89 17.1 6 1.6 27.6 6 2.4 28.6 6 2.9
Z-VAD-FMK 19.0 6 5.1 22.8 6 3.5 28.0 6 2.9
Table expresses cell death by pretreatment of A375 cells with metabolic inhibi-
tors respect to mock (cells treated with drug vehicle = DMSO). JAM test was per-
formed to quantify cell death. Values are reported as mean 6 SD of at least three
different experiments.
ap < 0.05 vs DMSO. Analysis was by ANOVA followed by Dunnett's test.
Negative values indicate an increased vitality of treated cells respect to DMSO
alone treated culture. Adenosine and MRE 3008F20 were challenged at 10 mM,
and HE-NECA at 100 nM.
Figure 11. ERK-1 and ERK-2 activated isoforms detection. (a)
A375 cells were starved for 5 d (untreated cells, lane 1) and treated for
2 h with HENECA 100 nM (lane 2), SCH 58261 10 mM (lane 3), Cl-IB-
MECA 10 mM (lane 4), MRE 3008F20 10 mM (lane 5), and adenosine
100 mM (lane 6). The detection of ERK-1 and ERK-2 phosphorylated
isoforms (top panel) and the total ERK isoforms (bottom panel) is shown.
(b) A375 cells treated with HENECA 100 nM (panel 1), Cl-IB-MECA
10 mM (panel 2), drug vehicle DMSO (panel 3), and with MRE 3008F20
10 mM (panel 4) were stained with antibody to ERK-1 and ERK-2
phosphorylated isoforms and detected by goat ¯uorescein isothiocyanate
anti-rabbit IgG. Faint and diffuse cytoplasmatic staining was present in
panels 2 and 3, whereas strong nuclear ¯uorescence was concentrated in
nuclei (panels 1 and 4) after 30 min of treatment. Original magni®cation
3 400.
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agree with previous results showing that A2A stimulation induces
phosphorylation of mitogen-activated protein kinase (Sexl et al,
1997; Arslan and Fredholm, 2000; Schulte and Fredholm, 2000).
Therefore, we attempted to determine in our model the origin of
the proliferative block induced by A3 stimulation. This anti-growth
signal blocks cells into G1-late cell cycle phase. We have found that
A3 blockage enhances adenosine function promoting cell
proliferation (Fig 4) and that A3 antagonists are able to improve
MEK activity (Fig 11A, lane 5; Fig 11B, panel 4): these results
emphasize the role of A3 as inhibitor of ERK activation. To sustain
this hypothesis we have found that Cl-IB-MECA was unable to
activate ERK phosphorylation (Fig 11A, lane 4; Fig 11B, panel
2). In conclusion, A3 stimulation arrests proliferation of A375 cells:
how this dysregulation of cell cycle progression affects homeostasis
of the cells has yet to be established.
More intriguing is the discovered signaling pathway that we have
depicted during adenosine-induced cell death. The molecular
mechanism promoted by A2A receptor engagement is not mediated
by caspase activation: these data agree with the absence of apoptosis
noted by ¯ow analysis. Furthermore, despite the ability of A2A to
increase cAMP levels (Merighi et al, 2001), we have noted that
PKA (cAMP dependent kinase, protein kinase A) is not involved in
killer signaling, which appeared to be mediated by PKC, ERK-1,
and ERK-2 phosphorylation. It has been reported that in
melanocytes, cAMP-dependent activation of ERK is mediated by
B-Raf (kinases of Raf superfamily kinases), but not by PKA (BuscaÁ
et al, 2000). This model could explain the absence of PKA
involvement on A2A cell-death signaling: A2A improves adenylyl
cyclase activity that in turn promotes PKA-independent ERK
activation. It has been reported that PKC could induce and activate
MAP/ERK signaling pathway through the activation of Ras
(Miranti et al, 1999) and PKC has been shown to stimulate adenylyl
cyclases (Marjamaki et al, 1997). Prompted by these data we
hypothesized the existence of cross-talk between PKC and cAMP-
Ras-ERK pathways in two ways: (i) PKC may activate directly
Ras, and (ii) PKC may improve adenylyl cyclase activity resulting
in increased cAMP levels that in turn activate Ras.
Despite the consolidated role of MEK as anti-apoptotic agents,
recent evidence proved that hyperoxia, nitric oxide, some anti-
cancer drugs (taxol and resveratrol), and de novo-synthesized
ceramide induced cell death by ERK-1 and ERK-2 activation
(Petrache et al, 1999; Blazquez et al, 2000; Bacus et al, 2001; She et
al, 2001). Further studies are necessary to investigate how ERK
activation (mediated by adenosine or by other factors) could
modulate cell death of melanocytic cells.
In conclusion, this study explains the con¯icting effects of
adenosine on malignant melanoma cells resulting from simultan-
eous activation of A2A and A3 adenosine receptors. We hypothesize
that, in the presence of raised extracellular concentration of
adenosine (during hypoxia, in¯ammation and inside tumor masses),
a cell expressing high levels of A3 adenosine receptor and low levels
of A2A adenosine receptor could be an advantage and positively
selected. These ®ndings persuade us to assert that the antagonists of
A3 adenosine receptors and the agonists of A2A adenosine receptors
may represent a potential new class of pharmacologic drugs in the
®ght against cancer, improving conventional anti-cancer therapies
by impairing clonal expansion and cell survival of malignant skin-
derived cells.
The authors are grateful to Dr Kristi Bemis (Institute of Human Virology,
University of Maryland, Baltimore, MD) for reviewing the manuscript.
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